England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the…
Articles by Marisa Wexler, MS
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of…
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat…
Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or…
The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found…
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of…
Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver…
AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early…
Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use…
Note: This story was updated Aug. 20, 2024, to correct that Livdelzi is not a first-in-class therapy for primary…